The BioGX Reagents offer laboratories a wide variety of syndromic groups from respiratory to sexual health, enteric pathogens, drug resistance, meningitis, transplant and tropical disease. With more than 20 years in the technology and operations industry, he has also served in various Operations and IT leadership positions at Battelle Memorial Institute, Nationwide Insurance and Cardinal Health. According to BD, BioGX developed the assay for the BD MAX system in their sample-ready, ready-to-use format to detect the presence of the SARS-CoV-2 virus. The OSRs are fine-tuned to ensure the highest performance in any lab setting, from a sophisticated lab, to a remote lab with limited infrastructure and resources. Dr. Iqbal is the Senior Vice President of Global Operations at BioGX and has over 20 years of experience in clinical and molecular diagnostics. for BD MAX System, which includes the following: BioGX SARS-CoV-2 Reagents for BD MAX System (lyophilized reagents for multiplexed detection of N1 and RNase P), BioGX … BioGX COVID-19, Flu A, Flu B, RSV RT-PCR for BD MAX™, Extraction-Free. “This is really a marvel of biochemistry because we’re able to put in a mixture of around a dozen components—the salts, enzymes, primers, and probes—that are usually assembled at the last minute and freeze-dry it. Customize your molecular diagnostics portfolio. BioGX SARS-CoV-2 HMP - N1, N2 & RNase P - High-Volume Multiplex Dr. Martinez has over 20 years of experience in molecular biology. Prior to joining BioGX, Mr. Hughes led efforts for a diverse range of companies with the development and implementation of certified quality management systems ranging from data storage devices with SONY Corporation, security & detention devices with Norment Security Group, textile manufacturing with Twitchell Corporation, combat vehicle manufacturing with General Dynamics, and therapeutic medical devices with Steris Corporation. Dr. Iqbal has an MBA and Ph.D as well as a Masters in Electrical Engineering degree from the University of Texas in San Antonio. He holds multiple patents in biotechnology, has authored or co-authored many publications, and has extensive experience in gene expression analysis, and in the design and development of rapid multiplex molecular tests for microbial and viral detection. He was also responsible for design and development of FISH automation systems at Abbott Molecular. 96 and 384-well plate PCR platforms 96 and 384-well plate PCR platforms The test detects viral RNA in pharyngeal and nasopharyngeal swab specimens and is designed to run on Becton Dickinson's BD Max system. Improved clinical outcomes are provided by the BD MAX™ System by combining complete automation of nucleic acid extraction and PCR thermocycling in a single platform. • The BioGX SARS-CoV-2 Reagents for BD MAX™ System can be used to test nasopharyngeal, nasal, mid-turbinate, and oropharyngeal swab specimens, nasopharyngeal wash/ aspirate or nasal aspirates. Portfolio of Tests: He brings over 20 years of experience in digital technology, e-commerce, and software product management in various industries and has held product leadership roles at Sprint, Travelocity, Capital One, Sabre, and cxLoyalty. The BioGX SARS-CoV-2 Reagents for the BD MAX™ System is available for purchase via Becton, Dickinson and Company directly. New mutation coverage, Estimate how Xfree™ can save money compared to your current testing while increasing capacity, faster turnaround time, and without requiring more automation, All the components for a complete RT-PCR test in one tube. Prior to founding BioGX, Dr. Vickery worked in sales and as a technical consultant at Cepheid. He is the recipient of the President awards and multiple service & innovation awards at Abbott. Hologic's (NASDAQ:HOLX) Panther Fusion SARS-CoV-2 Assay and its Aptima SARS-CoV-2 Assay are also among the most sensitive on the FDA's list, as is Becton, Dickinson's BioGX … He holds multiple patents in biotechnology, has authored or co-authored many publications, and has extensive experience in gene expression analysis, and in the design and development of rapid multiplex molecular tests for microbial and viral detection. format where all required reagents for real-time PCR are lyophilized in a single tube. Dr. Martinez manages global marketing of BioGX manufacturing services; expanding our portfolio of IVD products; managing the global technical support efforts of all molecular diagnostic products; and manages a team of scientists responsible for product and technology innovation in conjunction with existing corporate partnerships. BioGX SARS-CoV-2 Reagents for BD MAX™ System– BD April 2, 2020 Disease 2019 (COVID-19) 2 give a positive result that is wrong (a false positive result). Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 … BD SARS-CoV-2 Package Insert; BioGX SARS-CoV-2 Reagents for BD MAX™ System. Expand your molecular diagnostics menu with BioGX Sample-Ready™, custom-designed reagents, mixed and lyophilized in one tube to run on a platform of your choice. Before joining BioGX, Dr. Iqbal led the Abbott Diagnostics Global Service & Support specifically for informatics, core lab automation, immunoassay and clinical chemistry systems at Abbott Diagnostics. Merchant has a proven track record of taking complex business needs and transforming them into successful digital and mobile products and solutions. Dr. Shahin Iqbal joined BioGX in 2019. Dr. Martinez holds a BA in Biology from Boston University and a Ph.D. in Microbiology from The Georgia Institute of Technology. Prior to entering graduate school, Dr. Vickery worked as an executive in the lowbed trailer industry for almost 10 years, pioneering the sale of American made heavy equipment transport trailers into China (ROC) and Japan during his tenure in the industry, and resupplying the oilfields of Kuwait with specialized trailers after the Gulf War. The test is offered in BioGX’s trusted, easy to use Sample-Ready ™ format where all required reagents for real-time PCR are lyophilized in a single tube. The BioGX multiplex COVID-19, Flu A, Flu B and RSV test is intended for qualitative detection of RNA specific to SARS-CoV-2,  Influenza A, Influenza B, and Respiratory Syncytial Virus A/B that may be present in Pharyngeal and Nasopharyngeal swab collections in transport media and saline, obtained from individuals at risk of respiratory viral infections. Dr. Martinez joined BioGX in 2015. Enables any lab to quickly expand their molecular diagnostics menu, reduce outsourcing and maximize revenue, Optimizes testing performance and sensitivity, Allows transport and storage at room temperature. The BioGX SARS-CoV-2 Reagents for BD MAX™ System is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from the 2019-nCoV in nasopharyngeal and oropharyngeal swab samples from patients who meet COVID-19 clinical and/or epidemiological criteria. degree in Physics and both M.S. Our Open Source Reagents (OSRs) manufacturing service offers laboratories an excellent option to outsource manufacturing of their Laboratory Developed Tests (LDTs). BioGX developed the assay for the BD MAX™ System in their Sample-Ready™ ready-to-use format to detect the presence of the SARS-CoV-2 virus, the cause of COVID-19. Prior to joining Abbott, Dr. Iqbal was head of operations, quality & regulatory, systems development and manufacturing of IHC systems at BioGenex in California. Dr. Shazi Iqbal has over 20 years of experience building healthcare technologies and businesses in business development, corporate sales, global marketing and product development. BioGX has been granted FDA-EUA for its molecular test on SARS-CoV-2. The tests will be run on the BD Max molecular diagnostic platform, which can process 24 samples simultaneously. Mr. Curtis has spent much of his career leading Operation and IT consolidations, Cloud technology identification and implementation, process design, improvement and efficiency initiatives. The BioGX COVID-19, Flu A, Flu B, RSV – RT-PCR for BD MAX™ is a multiplex real-time reverse transcriptase, polymerase chain reaction (PCR) assay for use on the BD MAX™ platform for the combined qualitative detection of the presence of RNA from Influenza A, Influenza B, RSV A, RSV B, SARS-CoV-2 and a Sample Processing Control. BioGX kits can be shipped anywhere in the world with no refrigeration required. This webinar includes an insightful overview of BioGX and what we do. We are very pleased with the reliability and performance of this complex respiratory panel. The BD MAX™ System is a fully integrated and automated molecular diagnostic platform already in use at thousands of laboratories worldwide. The simultaneous detection of COVID-19, Flu A, Flu B and RSV during Flu season would help further augment the BD MAX. Dr. Vickery holds a B.S. Mr. Curtis studied Management Information Systems and Marketing at Franklin University. and Ph.D. degrees in Biology (molecular biology and molecular genetics focus – both prokaryotic and eukaryotic). Dr. Vickery founded BioGX in 2007 and served as President and CEO until 2011. COVID-19/Flu Combo Test for BD MAX™ High volume, multi-platform COVID-19 tests; Extensive portfolio of CE-IVD marked products degree in Physics and both M.S. This Fact Sheet informs you of the significant known and potential risks and benefits of the use of the BioGX Xfree™ COVID-19 Direct RT-PCR. BioGX COVID-19, Flu A, Flu B, RSV – RT-PCR for BD MAX™ System. Mr. Dr. Martinez has over 20 years of experience in molecular biology. He has served at BioGX in various senior R&D and quality management roles prior to his current position as Senior Director of Product Development. BD BioGX SARS-CoV-2 for BD MAX™ System Samples can be analyzed from start to finish … He holds an MBA and MS Innovation and Entrepreneurship degrees from University of Texas in Dallas and received his BS in Management Information Systems from Oklahoma State University. Mr. Hughes joined BioGX in 2015. Mr. Flexibility and standardization allow you to … Mr. Blackstone joined BioGX in 2007. Simultaneously detect SARS-CoV-2, Flu A, Flu B, RSV The BioGX SARS-CoV-2 Reagents for BD MAX™ System is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in nasopharyngeal and oropharyngeal swab samples from individuals suspected of COVID-19 by their healthcare provider. Dr. Iqbal is the Senior Vice President of Global Operations at BioGX and has over 20 years of experience in clinical and molecular diagnostics. The assay is based on the same viral RNA targeting sequences and real-time PCR detection method as the test developed by the U.S. Centers for Disease Control and Prevention ( CDC ). Christopher has a BSE from Auburn University and an MBA from Troy State University. The assay is provided in a BioGX proprietary Sample-Ready™ lyophilized format sealed in a BD MAX™ tube. The BD MAX™ System is a fully-integrated, automated platform that performs nucleic acid extraction and real-time PCR providing results for up to 24 samples across multiple syndromes in less than three hours*. Launched 44+ LUO tests for BD MAX™. He was also responsible for design and development of FISH automation systems at Abbott Molecular. This Fact Sheet informs you of the significant known and potential risks and benefits of the use of the BioGX Xfree™ COVID-19 Direct RT-PCR. QuantStudio™ 5 Extracted Sample Run File 1. Mr. Blackstone previously served for eight years at the US Food and Drug Administration and as a Commissioned Research Officer in the US Public Health Service Commissioned Corps where he achieved the rank of Lieutenant Commander. The BD MAX ™ system offers you an efficient path to improved clinical outcomes by combining and automating extraction and thermocycling into a single platform capable of running both FDA-cleared and open system assays. This webinar includes an insightful overview of BioGX and what we do. Xfree™ COVID-19 Direct RT-PCR Test - Extraction-Free! CE-IVD Marked, Your Assay. Dr. Iqbal holds multiple patents on optical sensors for covers slips, automation systems development, RFID applications and robotics for system dispensing. George Blackstone received his Master of Science degree from Louisiana State University. For EU inquiries: EU@BIOGX.COM | +31.20.893.4261. BioGX offers an expanding menu of reagents* manufactured for use with the BD MAX™ System. Dr. Iqbal received a Ph.D. in Biology from University of Texas at San Antonio, holds two master’s degrees in Biochemistry and Biotechnology and has several patents and publications to his name. Dr. Shazi Iqbal joined BioGX in 2011 as CoFounder and Chief Executive Officer of the Company. See our extensive menu of high-performance reagents, For US inquiries: INFO@BIOGX.COM | +1.205.250.8055 Dr. Vickery founded BioGX in 2007 and served as President and CEO until 2011. Any Platform. Mr. Mohammed Merchant joined BioGX in 2020 as Senior Director of Digital Product Management & Marketing, responsible for managing all digital applications and assets. The assay is based on the same viral RNA targeting sequences and real-time PCR detection method as the test developed by the U.S. Centers for Disease Control and Prevention (CDC). Merchant has a proven track record of taking complex business needs and transforming them into successful digital and mobile products and solutions. Just Add Water™No extraction reagents required The BioGX SARS-CoV-2 Reagents for BD MAX™ System is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from the 2019-nCoV in nasopharyngeal and oropharyngeal swab samples from patients who meet COVID-19 clinical and/or epidemiological criteria. Furthermore, an Introduction to Xfree™, our extraction-free, high-throughput direct RT-PCR test for COVID-19, provides an understanding of the benefits for laboratories all over the world, associated with this groundbreaking product. The BioGX SARS-CoV-2 Reagent kit runs on the fully automated BD MAX™ System, that is used by hundreds of laboratories in nearly every state in the US. Mr. Curtis studied Management Information Systems and Marketing at Franklin University. The aforesaid tests will be run on the coveted BD MAX molecular diagnostic platform, which is already in use in nearly every state across the United States. The BioGX SARS-CoV-2 Reagents for BD MAX™ System is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in nasopharyngeal and oropharyngeal swab samples from individuals suspected of COVID-19 by their healthcare provider. Mr. Blackstone has designed and directed the development of over 100 multiplex real time PCR products in the fields of food safety, water quality, pharma QC, and clinical diagnostics. Prior to Cepheid, Dr. Vickery worked at the FDA as a University of Maryland JIFSAN postdoctoral fellow at the University of Maryland, and later served as the Lead for Molecular Methods Development at the U.S. FDA Gulf Coast Seafood Laboratory. Prior to founding BioGX, Dr. Vickery worked in sales and as a technical consultant at Cepheid. Mr. Curtis joined BioGX in 2016. Fully Automated BD BioGX SARS-CoV-2 for BD MAX™ System Fully Automated Joey Curtis, Senior Director of Global Operations and Technology, Mohammed Merchant, Sr. Director, Digital Product Marketing, Robert Martinez, Ph.D, Director of Marketing, Product Support and Innovation, Michael Vickery, PhD, EVP, Chief Scientific Officer, Christopher Hughes, Senior Director of Quality and Regulatory Affairs, George Blackstone, Senior Director of Product Development, COVID-19, Flu A, Flu B, RSV – RT-PCR for BD MAX™ System, SARS-CoV-2 HMP – N1, N2 & RNase P Multiplex, https://secureservercdn.net/104.238.69.231/3af.a9a.myftpupload.com/wp-content/uploads/2020/08/logo-240.png, BioGX Announces FDA Emergency Use Authorization Submission of Extraction-Free Direct RT-PCR Test for COVID-19, All BioGX COVID-19 tests have coverage for new strains of SARS-CoV-2, This Fact Sheet informs you of the significant known and potential risks and benefits of the use of the BioGX, High volume, multi-platform COVID-19 tests, Extensive portfolio of CE-IVD marked products.